Follow
Mark D Pankau
Mark D Pankau
Umoja Biopharma
Verified email at uw.edu
Title
Cited by
Cited by
Year
Dynamics of HIV DNA reservoir seeding in a cohort of superinfected Kenyan women
MD Pankau, DB Reeves, E Harkins, K Ronen, W Jaoko, K Mandaliya, ...
PLoS pathogens 16 (2), e1008286, 2020
482020
Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering
KR Michels, A Sheih, SA Hernandez, AH Brandes, D Parrilla, B Irwin, ...
Journal for immunotherapy of cancer 11 (3), 2023
252023
Decay of HIV DNA in the reservoir and the impact of short treatment interruption in Kenyan infants
MD Pankau, D Wamalwa, S Benki-Nugent, K Tapia, E Ngugi, A Langat, ...
Open Forum Infectious Diseases 5 (1), ofx268, 2018
172018
Association between cytomegalovirus and Epstein-Barr virus viremia and human immunodeficiency virus DNA levels in the reservoir of Kenyan infants receiving antiretroviral therapy
JA Slyker, B Guthrie, M Pankau, K Tapia, D Wamalwa, S Benki-Nugent, ...
The Journal of Infectious Diseases 223 (11), 1923-1927, 2021
52021
Cytomegalovirus and Epstein-Barr virus viremia are associated with HIV DNA levels in the reservoir of Kenyan infants on antiretroviral therapy
JA Slyker, B Guthrie, M Pankau, K Tapia, D Wamalwa, S Benki-Nugent, ...
J. Infect. Dis 223 (11), 1923-1927, 2020
52020
HIV reservoir size is not increased by short ART interruption in Kenyan infants
M Pankau, D Wamalwa, S Benki-Nugent, A Langat, K Tapia, ...
Conference on Retroviruses and Opportunistic Infections. Seattle, USA, 2017
22017
Generation of synthetic cytokine receptor-induced cytotoxic innate lymphocytes (iCILs) from iPSCs as off-the-shelf cancer therapeutics
S O'Hara, T Rowland, R Koning, D Vereide, M Hoffmann, A Yingst, ...
Cancer Research 82 (12_Supplement), 547-547, 2022
2022
Gene Editing/Gene Therapies: A SYNTHETIC CYTOKINE RECEPTOR PLATFORM FOR PRODUCING CYTOTOXIC INNATE LYMPHOCYTES AS “OFF-THE-SHELF” CANCER THERAPEUTICS
D Vereide, S O’Hara, T Rowland, R Koning, M Hoffmann, A Yingst, ...
Cytotherapy 24 (5), S40-S41, 2022
2022
VivoVec: A Novel Lentiviral-Based In Vivo CAR T Cell Generation Platform with Viral Particle Surface Engineering Incorporating T Cell Activating and Co-Stimulatory Ligands
C Nicolai, J Qin, M Pankau, W Wu, E Naibert, G Hamilton, M Chen, ...
MOLECULAR THERAPY 30 (4), 417-417, 2022
2022
Preclinical Activity and Safety of UB-VV100, A Novel Lentiviral Vector Product Designed for Selective and Effective In Vivo Engineering of Therapeutic Anti-CD19 CART Cells for …
AH Brandes, S Geisinger, A Sheih, A Ting, K Michels, SA Hernandez, ...
MOLECULAR THERAPY 30 (4), 579-580, 2022
2022
UB-VV100, a Novel Platform for In Vivo Engineering of Therapeutic Anti-CD19 CAR T Cells, Shows Effective T Cell Transduction, B Cell Depletion, and Tumor Control in a Humanized …
KR Michels, AM Sullivan, CJ Nicolai, SH Lopez, L Beitz, J Whalen, ...
MOLECULAR THERAPY 29 (4), 310-310, 2021
2021
Dinâmica do reservatório latente do HIV-1
MD Pankau
2019
Dynamics of the HIV-1 Latent Reservoir
MD Pankau
2019
The system can't perform the operation now. Try again later.
Articles 1–13